Close Menu

NEW YORK (360Dx) – With the advent of new cancer immunotherapies, and older such therapies being used for new indications, the use of PD-L1 testing to determine which patients may best respond to them has moved into the forefront of cancer care. 

But for clinicians facing a mottled molecular diagnostic landscape, deciding on the right test is hardly simple. The different tests may not be cross-compatible or interchangeable, and clinicians are forced to forage through complicated data and considerations for what they say should be a straightforward choice. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.